Articles tagged with Tumor Cells
A study found that younger and female patients accumulate more cancer-causing genetic mutations, making them less visible to the immune system. This selective pressure leads to poorer response rates to immunotherapy.
Breast cancer cells send pro-tumorigenic messages to normal cells through extracellular vesicles, reprogramming mitochondrial function and promoting migration. This process may provide a novel target for disrupting cancer progression.
Scientists discovered that identifying tumor-associated macrophage patterns in lung tumor tissue enables the prediction of disease progression. The study found that a higher number of tumor-promoting macrophages near the invasive margin is associated with lower patient survival rates.
Cancer cells release small vesicles called exosomes that can re-programme surrounding cells, driving tumour growth and metastasis. The newly discovered Rab11a-exosomes may help cancers evade treatments.
Tiny finger-like projections called filopodia play a crucial role in invasive behavior of rare lung cancer cells. The cells have longer filopodia than their counterparts, which is linked to the gene MYO10, stabilizing these structures. This discovery could help develop treatments that prevent cancer from spreading.
Cancer researchers identified a previously unseen cell state that enables tumors to develop resistance to chemotherapy, and found this adaptable cell type in every tumor they examined. This discovery offers hope for developing targeted therapies to combat cancer's adaptability and provide longer-lasting remissions.
Researchers at MIT and Harvard University have mapped out an additional layer of control guiding tumor evolution through epigenomic alterations. They identified 11 chromatin states that cancer cells can pass through as they become more aggressive, and found a key molecule linked to advanced lung cancer forms.
A new approach combines CAR-T cell technology with natural killer cells to enhance tumor-fighting ability and reduce side effects. The merged immunotherapy shows promise in treating certain blood cancers, such as leukemia, and may be safer than traditional CAR-T cell therapy.
Researchers have demonstrated the potential of a leukemia drug, arsenic trioxide, to treat medulloblastoma, a type of brain cancer most common in children. The drug made tumor cells more sensitive to radiation therapy and proved capable of killing tumor cells and preventing new colony formation.
Fox Chase Cancer Center and Ben-Gurion University have received a $320,000 grant to test an immune-stimulating antibody developed by BGU researcher Angel Porgador for treating multiple myeloma. The antibody helps the immune system kill multiple myeloma tumor cells and may work on many different types of tumors.
Researchers developed engineered natural killer immune cells expressing a PD-L1 CAR that directly kill tumour cells in mice and humans. The treatment also reduces the numbers of immunosuppressive myeloid cells harbouring PD-L1.
Researchers at Cold Spring Harbor Laboratory found that interfering with cholesterol storage can stop pancreatic cancer cell growth in mice and lab-grown pancreas models. The study suggests a new strategy for treating deadly disease by targeting an enzyme called SOAT1.
Researchers found that a gene's checkpoint mechanism can sometimes allow cells to divide abnormally, leading to worse damage. This discovery has important implications for treating cancer and understanding the inner workings of cells.
Researchers developed a new single-cell DNA sequencing method to analyze the genetic diversity of individual cells within a tumor. The study revealed at least four major sub-populations of cells that are expected to have mutated from the original cancer cell, providing important insights into how cancer progresses and spreads.
Researchers discovered that platelet-derived growth factor B (PDGFB) plays a key role in maintaining the vascular barrier in tumors, reducing the spread of cancer cells. In mouse models, PDGFB deletion from platelets led to increased circulating tumor cells and metastasis.
The new technology uses low-frequency ultrasound to detonate tumor-targeted microbubbles, destroying up to 80% of cancer cells. An immunotherapy gene is co-injected to enhance the immune response, targeting and destroying remaining cancer cells.
Scientists at the University of Würzburg have identified thousands of cryptic HLA peptides in tumor immunopeptidomes using a novel bioinformatics method. These peptides may serve as effective targets for cancer immunotherapies and vaccines against virus-infected cells.
Researchers at UC San Diego School of Medicine discovered a new way to treat cancer by manipulating macrophages, immune cells found in tumor tissues. IRE1α, a molecule regulating the unfolded protein response, was shown to boost PD-L1 levels on macrophages, allowing tumors to evade the immune system.
Researchers at Nagoya University have developed a near-infrared photoimmunotherapy (NIR-PIT) treatment targeting podoplanin-positive cells in malignant pleural mesothelioma (MPM). NIR-PIT has shown promise in reducing fluorescence from cancer-tagged cells and demonstrating anti-cancer effects.
A phase I/II clinical trial suggests that vaccines prepared from a patient's own tumor cells may prevent mantle cell lymphoma from returning after treatment. The vaccines are a safe and effective way to induce the immune system to attack any tumor cells that could cause disease relapse.
Researchers found that removing CAVIN1 from stromal cells allows prostate cancer cells to feed on lipids, fueling growth and spreading. This leads to aggressive tumor behavior, including invasive and metastatic behavior.
Researchers developed a new method, HT-DBP, to screen thousands of drugs in freshly collected human tumor cells, potentially leading to more accurate and personalized treatment. The technique indicates which drugs are most likely to be effective against specific cancers, improving physicians' ability to tailor treatment.
Researchers create sugar-tagged drug compounds to target chemotherapy-resistant prostate cancer cells, exploiting the Warburg effect. The new compound shows improved efficiency in killing cancer cells compared to traditional chemotherapeutic drugs.
Researchers at Tokyo University of Agriculture and Technology have developed a new cell culture process that can replicate cancer cells from diseased bladder tissue in dogs, allowing for more efficient cancer research. This breakthrough method enables the diagnosis and treatment of cancer without using costly stem cell products or trad...
Researchers discovered resistance to tumor inhibitors arises from gradual adaptation to selective pressures, providing opportunity for effective therapies. The study advances in evolution of resistance and offers evolutionary-informed therapies for future treatments.
Researchers identified a type of cell fusion between cancer cells and white blood cells called tumor-macrophage fusion (TMF), where the size and number of TMFs may predict disease-free survival. Larger TMFs were linked to shorter disease-free survival rates.
Scientists at ChristianaCare's Gene Editing Institute have developed a new CRISPR advance that can safely target and disable the NRF2 gene linked to a bleak prognosis in lung cancer tumors. This approach aims to improve the efficacy of conventional chemotherapy and radiation treatments while minimizing harm to normal cells.
Research reveals that cancer clusters exhibit higher metastatic potential than single cells due to increased resistance to natural killer cell-mediated destruction. The study suggests enhancing the ability of activated NK cells to eliminate cluster metastasis could provide a complementary cancer therapy approach.
Piya Ghose, an assistant professor of biology at UTA, has established a new lab with $2 million in CPRIT funding. Her research focuses on programmed cell death, which can lead to cancer through tumor creation. Ghose's work aims to understand how tumors behave throughout the body and could lead to breakthroughs in cancer treatment.
Researchers have discovered a new class of immunotherapy that targets myeloid immune cells and slows tumor growth by inhibiting the c-Rel molecule. The treatment showed promising results in both human cells and mouse models, shrinking tumors by up to 80% and reducing immune suppressor cells.
Researchers have developed a new combined treatment using a senescence inducer and a senolytic nanoparticle that selectively removes senescent cells, delaying tumor growth and reducing metastasis in aggressive breast cancer. The study provides new therapeutic methodologies to be developed in subsequent stages and clinical trials.
Researchers have made a breakthrough in targeting non-cancerous senescent cells to slow down liver tumor growth. The study, led by Celeste Simon, found that these cells play a crucial role in promoting tumor progression and can be selectively targeted using senolytics.
Mutations in TP53 and concomitant mutant p53 proteins in cancer cells have been found to accelerate tumorigenesis and metastasis. The researchers found that the combination of gain of function mutations and loss of heterozygosity provides protection against cell death, promoting a fibrotic microenvironment and inflammation pathways.
PD-1/PD-L1 inhibitors have shown promise in treating non-small cell lung cancer, but the proportion of patients who benefit from these treatments is relatively small. Researchers are exploring biomarkers to identify potential beneficiaries and improve cost-effectiveness.
Researchers discovered that cancer stem cells' ability to synthesise proteins is the essence of their pluripotency and contributes to unlimited tumour growth. By blocking this capacity, tumours can be halted in an irreversible manner.
A HKBU-led research team developed a novel antiviral drug that selectively disrupts EBV protein, leading to tumour shrinkage and improved survival rates in animal models. The drug has shown promising results in targeting latent EBV infection, providing new treatment options for nasopharyngeal carcinoma.
Researchers develop novel nanoplatform to induce ferroptosis in tumor cells, targeting multiple types of tumors while sparing healthy cells. The complexed doxorubicin and ferrous ions promote lipid peroxidation, leading to severe ferroptic damage.
Researchers at TUM have discovered a novel mechanism that inhibits cancer-specific immune responses, leading to the development of new immunotherapies. The discovery identifies a suppressive metabolite from glucose metabolism as a key factor in limiting cancer immunity.
Researchers discover that nutrient deficiencies in tumor cells trigger the release of cytokines and chemokines, attracting immune cells that inhibit effective attacks. The lack of blood supply is interpreted as a wound, triggering an inflammatory response that promotes angiogenesis and tumor growth.
Researchers at Moffitt Cancer Center have identified the PERK protein as a critical molecular pathway controlling immunosuppression in tumor cells. By targeting PERK, cancer patients may experience reactivation of their immune system and enhanced effectiveness of immunotherapy treatments.
A new study led by UT Southwestern scientists suggests that tumors can manipulate the cell death signaling pathway to evade an immune response after radiation. By blocking this pathway, researchers found that cancer cells can secrete more interferons, which triggers a tumor-fighting immune response.
Researchers at the University of Pennsylvania School of Medicine have discovered a way to modify PARP inhibitor compounds to increase their effectiveness in killing cancer cells. By structurally modifying veliparib, a previously ineffective compound, they were able to boost its ability to trap and kill tumor cells.
A virtual computational cell was built to predict cancer metastasis by analyzing the interaction of numerous molecules and signals within the tumor environment. The research found that hybrid cancer cells can be targeted using specific molecular signals and extracellular matrix proteins, offering new therapeutic strategies against cancer.
Researchers have identified a gene linked to brain cancer in children that can aid in diagnosis and treatment. Elevated levels of the TPR gene were found in 38% of ependymoma cases, and its deletion led to reduced cancer growth and tumor shrinkage when treated with rapamycin.
A team of scientists has developed a cancer diagnostics method that amplifies microRNA in live tumor cells using synthetic DNA and nanoparticles. This allows for the detection of tumor cells with high sensitivity, potentially leading to earlier diagnosis and improved treatment outcomes.
Researchers at UC have discovered a mechanism that could lead to new immunotherapies for patients with head and neck cancers. By understanding how calmodulin interacts with ion channels in immune cells, scientists may be able to develop new treatments to restore the ability of these cells to enter and kill tumors.
A new imaging agent has been developed to identify cancer cells and their supporting compromised cells. The compound binds to activated annexin A2 protein present in many solid tumors, allowing for targeted imaging and potential dual targeting of the tumor and surrounding cells with chemotherapy drugs.
A research team led by University of Würzburg scientists has found a way to inactivate the cancer protein NP63, which is crucial for squamous cell carcinoma growth. By using a preclinical inhibitor, they were able to switch off NP63's parking ticket remover and stop tumor cells from growing.
Scientists create micrometric scaffolding with gold nanoparticles to detect biomarkers and track cell displacement in real time. The SERS technology allows for precise monitoring of tumor growth and evolution, providing insights into cancer treatment.
A study found that a clinically available drug, prochlorperazine (PCZ), inhibits the internalization of receptors on tumor cells, increasing the ability of anticancer antibodies to bind and mount effective immune responses. This temporary inhibition improves the effectiveness of cancer treatments.
A study published in eLife has identified two strategies used by cancer to survive treatment with immunotherapies, including one that disables energy production in cancer-killing T-cells. Researchers found that some human cancer cells release molecules that inhibit the activity of energy-producing mitochondria in T-cells.
New research on cancer cells' interaction with their environment reveals the importance of physical cues in guiding cell migration. A novel optical tweezer-based tool probes mechanical cues to study tumor behavior.
The study found that SLC25A32 inhibition resulted in anti-proliferative effects on certain tumor cell lines, potentially by increasing reactive oxygen species. Treatment with riboflavin and glutathione rescued cancer cell proliferation upon SLC25A32 down-regulation.
Researchers at CNIO propose a novel approach using CDK4/6 inhibitors after chemotherapy to prevent tumor cells from resisting treatments. This strategy shows promising results in preventing tumor growth and death in mice with pancreatic adenocarcinoma, suggesting new avenues for improving cancer treatment.
Researchers developed a nanoparticle delivery method that tags implanted human cancer cells with molecular signals, making them visible to the immune system. The treatment showed promise in mice with melanoma and colon cancer, with some surviving up to 60 days without tumor growth.
Researchers discovered that healthy lung cells support the survival of breast cancer cells, allowing them to form secondary tumours. Targeting the growth of cell protrusions on breast cancer cells can prevent secondary tumour formation.
Scientists create tiny nanoparticles made of dendritic polyglycerols to target cancer cells via EGFR receptors. The particles are designed to visualize tumor cells using imaging techniques and can be modified to carry therapeutic agents, offering a potential therapeutic approach.
A Cornell-led team employed a statistical modeling technique from physics to analyze breast tumor cells' behavior in the microenvironment. They found that chemokine CCL19 caused targeted cancer cells to move faster and increased heterogeneity.
A team of researchers has created a detailed cell atlas of an entire salivary gland tumor in a mouse model, revealing that the tumor is composed of various cell types, including cancer stem cells. The study uses single-cell RNA sequencing technologies to identify these cells, which make up less than one percent of the tumor population.
Scientists have developed a new technique to analyze signaling molecules in individual cancer cells, revealing complex communication networks that contribute to tumor growth and treatment resistance. The technique, tested on bowel cancer cells, detected 28 key signaling molecules across six cell types in over 1 million cells.